EUA-20331-77952
3 vaccinations
10 coded responses
36 check-ins
9 free-text entries
1 call case
- Sex
- Female
- Age at first dose
- 41-45
- ZIP prefix
- 852 / AZ
- Registered
- 2020-12-19
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2020-12-19
Registered in v-safe
-
2020-12-19
Dose 1 — Pfizer-BioNTech
- 2020-12-19
-
2020-12-20
Health check-in — days 1–6 daily, dose 1Feeling: Good · Site: Pain · Muscle or body achesAdult check-in
- 2020-12-21
- 2020-12-22
- 2020-12-24
- 2020-12-25
-
2020-12-26
Health check-in — day 7, dose 1Feeling: Fair · Muscle or body aches, Fatigue or tirednessAdult check-in
- 2021-01-02
-
2021-01-09
Dose 2 — Pfizer-BioNTech
- 2021-01-09
-
2021-01-10
Survey response — days 1–6 daily, dose 2MedDRA: Dizziness — Feeling: Poor · Site: Pain · Chills, Headache, Joint pains, Muscle or body aches, Fatigue or tiredness, Nausea · Be unable to workFree text: Mild dizziness in the hours following vaccinationMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-01-10
-
2021-01-11
Health check-in — days 1–6 daily, dose 2Feeling: Good · Site: Pain · Muscle or body aches, Fatigue or tirednessAdult check-in
-
2021-01-12
Health check-in — days 1–6 daily, dose 2Feeling: Good · Site: Pain · Fatigue or tirednessAdult check-in
- 2021-01-13
- 2021-01-14
- 2021-01-15
-
2021-01-16
Health check-in — day 7, dose 2Feeling: Fair · Headache, Joint pains, Muscle or body aches, Fatigue or tiredness, DiarrheaAdult check-in
- 2021-01-23
- 2021-01-30
- 2021-02-06
-
2021-02-13
Survey response — day 35, dose 2MedDRA: Asthma, Pre-existing disease — Feeling: GoodFree text: Worsening asthma symptomsMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-02-20
- 2021-04-10
- 2021-07-10
-
2022-01-06
Dose 3 — Pfizer-BioNTech
-
2022-01-09
Survey response — days 1–6 daily, dose 3MedDRA: Axillary pain, Loss of personal independence in daily activities, Lymphadenopathy, Self-medication — Feeling: Good · Site: Pain · Be unable to do your normal daily activitiesFree text: Right axillary pain & lymphadenopathy limiting my daily activities and requiring OTC analgesics for pain control.MedDRA releases: 2024-11 · check-in free text available
-
2022-01-09
Survey response — 12 months, dose 2MedDRA: Lymphadenopathy — Feeling: Good · Be unable to do your normal daily activitiesFree text: Right axillary lymphadenopathy and pain s/p COVID-19 booster on 1/6MedDRA releases: 2024-11 · check-in free text available
-
2022-01-10
Survey response — days 1–6 daily, dose 3MedDRA: Axillary pain, Lymphadenopathy — Feeling: Good · Site: PainFree text: Mild axillary pain (much improved from prior) with improving lymphadenopathyMedDRA releases: 2024-11 · check-in free text available
- 2022-01-11
- 2022-01-13
-
2022-01-20
Survey response — day 14, dose 3MedDRA: Fatigue, Nasal congestion, Oropharyngeal pain, Pain — Feeling: FairFree text: Mild nasal congestion, faint sore throat, mild body aches & fatigueMedDRA releases: 2024-11 · check-in free text available
-
2022-01-27
Survey response — day 21, dose 3MedDRA: COVID-19 — Feeling: Good · Be unable to work or attend school, Be unable to do your normal daily activitiesFree text: COVIDMedDRA releases: 2024-11 · check-in free text available
-
2022-02-03
Survey response — day 28, dose 3MedDRA: Headache, Myalgia — Feeling: GoodFree text: Headache, myalgiasMedDRA releases: 2024-11 · check-in free text available
- 2022-02-10
- 2022-02-17
- 2022-04-07
-
2022-07-07
Survey response — 6 months, dose 3MedDRA: Fatigue, Headache, Oropharyngeal pain — Feeling: GoodFree text: Fatigue, headache, sore throatMedDRA releases: 2024-11 · check-in free text available
-
2023-01-07
Survey response — 12 months, dose 3MedDRA: Upper respiratory tract infection — Feeling: Good · Be unable to do your normal daily activitiesMedDRA releases: 2024-11
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2020-12-19 | Pfizer-BioNTech | |
| 2 | 2021-01-09 | Pfizer-BioNTech | |
| 3 | 2022-01-06 | Pfizer-BioNTech | No |
Call center
1 call center case
1 priority 2/3 (triaged and no follow up)
Free text
Release 1 — days 1–6 daily, dose 2
Systemic reaction (other): Mild dizziness in the hours following vaccination
Release 4 — day 35, dose 2
Symptoms: Worsening asthma symptoms
Release 10 — 12 months, dose 2
Symptoms: Right axillary lymphadenopathy and pain s/p COVID-19 booster on 1/6
Release 10 — days 1–6 daily, dose 3
Systemic reaction (other): Right axillary pain & lymphadenopathy limiting my daily activities and requiring OTC analgesics for pain control.
Systemic reaction (other): Mild axillary pain (much improved from prior) with improving lymphadenopathy
Release 10 — day 14, dose 3
Symptoms: Mild nasal congestion, faint sore throat, mild body aches & fatigue
Release 11 — day 21, dose 3
Symptoms: COVID
Release 11 — day 28, dose 3
Symptoms: Headache, myalgias
Release 12 — 6 months, dose 3
Symptoms: Fatigue, headache, sore throat
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Asthma | ✓ | ✓ | ✓ |
| SD | COVID-19 | · | · | ✓ |
| SD | Fatigue | · | · | ✓ |
| SD | Headache | · | · | ✓ |
| SD | Lymphadenopathy | · | · | ✓ |
| SD | Myalgia | · | · | ✓ |
| SD | Nasal congestion | · | · | ✓ |
| SD | Oropharyngeal pain | · | · | ✓ |
| SD | Pain | · | · | ✓ |
| SD | Pre-existing disease | ✓ | ✓ | ✓ |
| SD | Upper respiratory tract infection | · | · | ✓ |
| SRO | Axillary pain | · | · | ✓ |
| SRO | Dizziness | ✓ | ✓ | ✓ |
| SRO | Loss of personal independence in daily activities | · | · | ✓ |
| SRO | Lymphadenopathy | · | · | ✓ |
| SRO | Self-medication | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release